The effect of spent coffee ground (SCG) loading, matrix ratio and biological treatment of SCG on poly(hydroxybutyrate) (PHB)/poly(lactic acid) (PLA) polymer blend.

This study investigates the effects of SCG embedded into biodegradable polymer blends and aimed to formulate and characterise biomass-reinforced biocomposites using spent coffee ground (SCG) as reinforcement in PHB/PLA polymer blend. The effect of SCG filler loading and varying PHB/PLA ratios on the tensile properties and morphological characteristics of the biocomposites were examined. The results indicated that tensile properties reduction could be due to its incompatibility with the PHB/PLA matrixSCG aggregation at 40 wt% content resulted in higher void formation compared to lower content at 10 wt%. A PHB/PLA ratio of 50/50 with SCG loading 20 wt% was chosen for biocomposites with treated SCG. Biological treatment of SCG using Phanerochaete chrysosporium CK01 and Aspergillus niger DWA8 indicated P. chrysosporium CK01 necessitated a higher moisture content for optimum growth and enzyme production, whereas the optimal conditions for enzyme production (50-55 %, w/w) differed from those promoting A. niger DWA8 growth (40 %, w/w). SEM micrographs highlighted uniform distribution and effective wetting of treated SCG, resulting in improvements of tensile strength and modulus of biocomposites, respectively. The study demonstrated the effectiveness of sustainable fungal treatment in enhancing the interfacial adhesion between treated SCG and the PHB/PLA matrix.

Detection and molecular characterization of calf diarrhoea bovine coronaviruses circulating in South Korea during 2004-2005.

Although the widespread occurrence of calf diarrhoea (CD) bovine coronavirus (BCoV) infections have been reported in most cattle producing countries, only the genetic differences in the BCoVs from American and Canadian isolates and/or strains have been identified and compared. Hence, it is unclear if the BCoVs circulating in the other countries have distinct genetic characteristics. The aim of this study was to determine the prevalence and genetic diversity of CD BCoVs based on the deduced amino acid (aa) sequences of the spike (S) and haemagglutinin/esterase (HE) proteins in South Korea. RT-PCR and nested PCR using the primer pairs specific to the nucleocapsid gene, BCoVs detected the BCoVs in 56 (15.6%) of 359 diarrhoeic faecal samples. Phylogenetic analysis of the entire S gene indicated that 10 Korean CD BCoV strains clustered with other Korean BCoV strains with different clinical forms but were different from the American and Canadian BCoV strains. Moreover, the phylogenetic data of the aa sequences of the HE gene revealed all the Korean CD strains to be distinct from the other Korean BCoV strains with different clinical forms. These results suggest that the Korean BCoVs cause endemic infections in diarrhoeic calves in Jeonnam province and have taken a different evolutionary pathway from the BCoVs in other countries. Moreover, the different BCoV strains are circulating in the different clinical forms in South Korea. These results also suggest that vaccines against the BCoVs can be developed with each Korean BCoV in different clinical forms.

Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.

Lamivudine is a new antiviral agent effective against hepatitis B viral (HBV) infections but can result in virus-drug resistance associated with mutations in the conserved 'YM552DD' motif of the HBV DNA polymerase. Due to their overlapping coding regions in the HBV genome, mutations in the DNA polymerase may result in substitutions in the hepatitis B surface antigen (HBsAg), albeit outside the antigenic 'a' epitope. Here we report the identification of a novel type of lamivudine-related mutations located in both the polymerase (YM552DD-->Y1552DD) and the 'a' epitope of HBsAg (Gly130-->Asp130). The same virus carried a HBsAg Gly145-->Arg145 mutation prior to therapy. Both the wild type HBV and lamivudine-related mutants with the Gly145-->Arg145 HBsAg mutation were suppressed following ganciclovir treatment, indicating a beneficial additive effect of both drugs against different forms of HBV mutants.

Significance of the minor i and t determinants of hepatitis B virus in hepatocellular carcinoma.

Stored sera from asymptomatic hepatitis B virus (HBV) carriers and hepatitis B virus surface antigen-positive hepatocellular carcinoma (HCC) patients were tested for HBV subtypes, such as subtype determinants d, y, w, r and also antigenic determinants isoleucine (i) and threonine (t) by direct S gene nucleotide sequencing. Significant changes in minor i and t determinants in hepatocellular carcinoma patients with adr hepatitis B carriers were seen. The adr subtype with t determinant was present in 14/25 (56%) of HCC patients compared with only two of 28 (7%) in asymptomatic hepatitis B carriers (P<0.001). However, the adr subtype with i determinant was present in nine of 25 (36%) of the HCC patients and also present in 24/28 (86%) of asymptomatic carriers (P<0.001). No significant changes were seen with the adw subtypes. These results show that i and t minor determinant changes are more common with adr subtypes associated with HCC than with the adw subtype. Whether these subtle changes are pathologically relevant or only a polymorphism of hepatitis B genotypes will depend on subsequent follow-up studies.

Acute viral hepatitis E: clinical and serologic studies in Singapore.

Seroprevalence of hepatitis E is now documented in many countries around the world, but studies of its clinical manifestations and serologic course have been confined to endemic areas. We have prospectively evaluated the occurrence, evolution, and outcome of acute hepatitis E in our patients. Fifteen patients (11 men, 4 women; median age: 41 years) were diagnosed to have acute, sporadic hepatitis E between July 1993 and January 1995; 10 of the 15 were followed up. Sera anti-hepatitis E virus (HEV) immunoglobulin (Ig)G and IgM antibodies and HEV ribonucleic acid in the blood and stool were tested at weeks 1 and 2; serial tests for hepatitis E antibodies and liver function were carried out at months 1, 3, 6, 9, 12, and 18. Coinfection with hepatitis A and superinfection on chronic hepatitis B were found in 3 and 2 patients, respectively. One patient had transient passage of virus in the stool, but none was viremic. Eighty-seven percent of patients lost their IgM antibodies within 3 months, but anti-HEV IgG, once present, persisted throughout follow-up. All patients but one had complete recovery. A higher than reported level of alanine transaminase (mean: 28.5 times normal) and the lack of viremia during acute infection in our patients may be due to increased immune-mediated viral clearance.

Processing of hydroxyapatite via microemulsion and emulsion routes.

Hydroxyapatite powders have been prepared by reacting CaCl2 and (NH4)2HPO4 in bicontinuous microemulsion, inverse microemulsion and emulsion, which have the same components as cyclohexane, non-ionic surfactant (NP5 + NP9) and aqueous solution. The characteristics of the resulting hydroxyapatite powders, such as the particle size, particle size distribution, chemical homogeneity and the degree of particle agglomeration, are strongly affected by the structure of the reaction medium. Both bicontinuous and inverse microemulsions led to the formation of much finer hydroxyapatite powders than that prepared from the emulsion composition. The two fine hydroxyapatite powders are sintered to a relative density of >95% theoretical density at 1000 degrees C, compared with a relative density of <73% theoretical density for the emulsion-derived one. The two microemulsion-derived hydroxyapatites also exhibit a higher sintered density and are more refined in grain size than that of the emulsion-derived one when sintered at 1200 degrees C for 2h.

Hepatitis E in Singapore--a seroprevalence study.

The seroprevalence of anti-HEV IgG was determined in a hospital-based population in a general medical unit. Patients who were otherwise well but admitted for acute, non-hepatological conditions represent the "healthy" general population, and those admitted primarily with liver disorders were studied. The seroprevalence of anti-HEV IgG was found to be 10.5% in the "healthy" population and 14.7% amongst those with liver diseases. The lack of travel history and past history of jaundice suggests presence of local cases and subclinical manifestation in some of the infected patients. There is an association between seroprevalence of hepatitis A and E, suggesting common predisposing factors for both infections. Anti-HAV IgG has a higher seroprevalence. Retesting of anti-HEV IgG in those who were initially positive found persistence of antibodies beyond twelve months. Both anti-HAV IgG and anti-HEV IgG were found more commonly in the older age groups.

Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults.

A cohort of seronegative preclinical medical and dental students and another cohort of seronegative national service recruits who were immunized intramuscularly with a reduced dose (10 micrograms) of plasma-based hepatitis B vaccine (Merck, Sharp & Dohme) at the start of the study and at 1 month and 6 months thereafter were followed up for 5 years and 6 years, respectively. Among the medical and dental students, antibody to hepatitis B surface antigen (anti-HBs) ( > or = 10 mlU/ml) was detected in 81% of the vaccinees at the end of the 5-year follow-up and the geometric mean titre (GMT) had dropped from 412.6 mlU/ml one year after completion of vaccination to 174.9 mlU/ml after 5 years. Antibody to hepatitis B core antigen (anti-HBc) was detected in 0.4-1.0% of the vaccinees but none was positive for hepatitis B surface antigen (HBsAg) during the follow-up period. Among the national servicemen, the anti-HBs seroconversion rate and GMT were considerably lower than those of the preclinical medical and dental students. At the end of the 6-year follow-up, 55% of the vaccinees were positive for anti-HBs ( > or = 10 mlU/ml) and the GMT had dropped from 80.7 mlU/ml one year after completion of vaccination to 30.4 mlU/ml after 6 years. Anti-HBc was detected in 8 (2.7%) and transient HBs antigenaemia in 2 (0.7%) of 293 vaccinees after 4 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Molecular epidemiology of hepatitis B virus vaccine variants in Singapore.

Perinatal infection with variants of hepatitis B virus occurs despite combined immunoprophylaxis with hepatitis B immunoglobulin and currently licensed plasma-derived and recombinant yeast hepatitis B vaccines. Several variants have been detected during a large study of infants born to carrier mothers in Singapore. The most frequent variant was a virus in which a single amino acid substitution Gly to Arg occurred at amino acid position 145 of the outer protein coat of the virus. Similar mutations have been described in Italy, Japan, the USA and a number of other countries. The emergence of antibody escape mutants is a cause for concern for the detection of virus and possibly for future immunization programmes.

The influence of medium components on secondary embryogenesis of winter oilseed rape, Brassica napus L. ssp. oleifera (Metzg.) Sink.

The secondary embryogenic potential of Brassica napus L. ssp. oleifera (Metzg.) Sink. ev. Primor could be maintained for many years on complete Murashige and Skoog's medium without diminution. Experiments were conducted to investigate the effects of reducing or deleting certain components of the medium on secondary embryogenesis. Secondary embryogenesis was found to be significantly suppressed when strength of iron in the medium was reduced. Secondary embryogenesis, completely suppressed in 'iron-free' medium, could be regained when iron was incorporated into the medium. Micronutrients and organic nutrients in the medium had no effect on secondary embryogenesis. A reduction in the strength of the medium or its macronutrients decreased secondary embryogenesis significantly.

Clearance of neonatal antiHBc following hepatitis B vaccination: relationship to antiHBs levels.

The persistence of antiHBc following hepatitis B virus (HBV) infection is sometimes regarded as evidence of a past infection, and the antiHBc inhibition of T-cell cytotoxic killing of HBV may be one way of tolerance leading to the carrier state. A model for studying the possibility of an immune tolerance occurring in the human situation was to observe the natural clearance rate of total antiHBc in babies who have acquired naturally maternal transferred antibodies, and to compare antiHBcIgG clearance and development of hepatitis B surface antigenaemia with the level of antibody to HBsAg (antiHBs), which is normally known to be virucidal. Two hundred and ninety-one normal infants who received hepatitis B vaccination in 1984 were followed and studied at six months, one, two and four years. AntiHBc was not found in any control infants born of HBsAg negative mothers. One child became antiHBc positive at four years reflecting acquired infection when antiHBs level had fallen to 36 mIU per ml. AntiHBc cleared in 66% of HBsAg pos./'e' neg. children at one year and completely by two years. In contrast, antiHBc clearance in children born of HBsAg pos./'e' pos. was inversely related to the antiHBs levels. Those with antiHBs levels over 50 mIU per ml cleared antiHBc more rapidly and were HBsAg negative, whereas in 28/49 (57%) HBs antigenaemia were associated more often with antiHBs under 10 mIU per ml and in 2/43 (5%) at levels between 11 to 50 mIU per ml. Two children who had later developed HBs antigenaemia in the presence of antiHBs after responding to earlier passive-active immunisation, suggest either defective antiHBs and/or the development of mutants or variants.(ABSTRACT TRUNCATED AT 250 WORDS)